Boehringer Hits Above The Belt With Zantac Purchase
This article was originally published in The Tan Sheet
Executive Summary
Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business